EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Acucela Gets FDA Fast Track

Acucela and its partner, Japan-based Otsuka Pharmaceutical, said today they have received “Fast Track” designation for an application to market a new drug for the “dry” form of age-related macular degeneration. The designation means that the companies will  be able to file data on their drug,  ACU-4429, as it becomes available, and which makes it possible for the companies to get a faster-than-usual six-month review that is sometimes given to applications to treat serious or life-threatening conditions.